查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球旅行疫苗市场（旅行前疫苗）-2022-2029
市场调查报告书
商品编码
1140728

全球旅行疫苗市场（旅行前疫苗）-2022-2029

Global Travelers Vaccines Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

旅游业的增长是市场增长的驱动力

旅游业的发展和旅行相关疾病的发病率激增是旅行者疫苗市场的主要增长因素。製药和生物技术公司对新疫苗研发的投资增加，以及国际旅行者更多地采用疫苗，这些都推动了对旅行者疫苗的需求。此外，政府举措的增加以及通过电子和印刷媒体提高认识是推动市场增长的因素。然而，缺乏疫苗製造专业知识和薄弱的冷供应链管理是阻碍市场增长的因素。

严重副作用的低风险也有助于市场增长。除了对胎儿产生严重副作用的极低风险外，各种非营利组织的适当教育和意识计划也是支持市场增长的因素。新兴国家和欠发达国家对疫苗外包的日益关注为推动旅行者疫苗市场提供了机会。由于出国旅游人数的增加以及疫苗接种率的提高，预计会出现增长。

地理渗透

北美是预测期内的主要地区。

该研究按地区分析了全球市场的旅行疫苗市场，包括北美、欧洲、亚太地区、南美、中东和非洲。

按地区划分，预计北美将在预测期内主导全球人类疫苗市场。在北美，预计联合疫苗市场份额将增长，其次是重组疫苗和减毒疫苗市场。在欧洲，疫苗需求的增加和研发支出的增加正在推动旅行疫苗市场的发展。

此外，由于医疗基础设施的改善和政府为实施教育和宣传计划而增加的支出，亚太地区已成为旅行疫苗的新兴市场。在中东和非洲国家，医疗保健行业和经济发展正在推动加强旅行者疫苗市场。然而，定价问题是製约市场增长的一个因素。沙特政府在该国实施了常规流感、流感和其他疫苗计划，为旅行者的疫苗市场创造了机会。

竞争格局

由于主要食品品牌的存在，旅行者的疫苗市场竞争激烈。对全球市场增长做出贡献的主要旅行疫苗公司有Baxter International, Abbott Laboratories, Crucell Vaccine, Pfizer, Emergent Biosolutions, Hoffman-La Roche, Dynavac Technologies, GSK Group, Shenzhen Kangtay Biological Products Co. Ltd., Takeda Pharmaceutical Company Limited (U.S.), Zydus Cadila等。主要参与者正在为旅行疫苗市场的全球增长采取新产品发布和扩张战略。一些主要参与者正在遵循收购策略来扩展业务。例如，2021 年 12 月，全球 MedTech 领导者 Baxter 完成了对 Hillrom 的收购。此次收购加速了公司在全球范围内改变医疗保健和推进患者护理的愿景。Baxter 是一家临床阶段的生物製药公司，以 156.00 美元现金收购 Hill-Rom 普通股的每股流通股，将收购价格定为 105 亿美元。2022年6月，辉瑞完成了对ReViral的收购。此次收购帮助扩大了公司有前景的候选治疗药物组合，包括顺纳托韦，一种口服抑製剂，旨在阻断 RSV 病毒与宿主细胞的融合。此次收购进一步证明了开创性科学的进步。2021年12月，辉瑞将以每股100美元的价格收购Arena Pharmaceuticals，这是一家临床阶段的公司，开髮用于治疗多种免疫炎症性疾病的创新潜在疗法，总股本价值约为67亿美元。

COVID-19 对全球旅行疫苗市场的负面影响。

COVID-19 无疑阻碍了全球旅行疫苗的发展。由于各国政府实施的国际旅行禁令，2020 年的国际旅客人数有所减少。因此，对旅行者疫苗的需求减少，导致市场价值从 2020 年开始下降。

自 COVID-19 以来，旅游业蓬勃发展，预计对健康和安全的日益增长的兴趣将推动对旅行者疫苗的需求。由于这种大流行，旅行者疫苗在明年将经历非常快速的增长。

全球旅行者疫苗市场报告提供对大约 56 个市场数据表、47 个数字和 170 页的访问。

目录

第一章 调查方法和范围

  • 调查方法
  • 调查目的和范围

第二章市场定义和概述

第三章执行摘要

  • 按类型划分的市场细分
  • 按应用划分的市场细分
  • 区域市场细分

第四章市场动态

  • 市场影响因素
    • 促进者
      • 旅游业和旅游业的增长
    • 抑製剂
      • 副作用风险低
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 价值链分析
  • PEST分析
  • 定价分析
  • 监管分析
  • 保险报销分析
  • 未满足的需求
  • 专利趋势

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 中的价格动态
  • 供需谱
  • 大流行期间与市场相关的政府努力
  • 製造商的战略举措
  • 概括

第 7 章 按类型

  • 脑膜炎球菌疫苗
  • 日本脑炎疫苗
  • 黄热病疫苗
  • 肝炎疫苗
  • 霍乱疫苗
  • 其他

第 8 章 按用途

  • 游客
  • 学生
  • 工人
  • 其他

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区
  • 中东/非洲

第 10 章 竞争格局

  • 竞争情景
  • 市场/份额分析
  • 併购分析

第十一章公司简介

  • Baxter International
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Abbott Laboratories
  • Crucell Vaccines
  • Pfizer Inc.
  • Emergent BioSolutions
  • Hoffman-La Roche Ltd.
  • Dynavax Technologies Corporation
  • GSK group of companies
  • Shenzhen Kangtay Biological Products Co. Ltd.
  • Takeda Pharmaceuticals U.S.A. Inc
  • Zydus Cadila（List Not Exhaustive）

第 12 章 重要注意事项

第 13 章 数据管理

简介目录
Product Code: DMHCIT3104

Market Overview

Travelers Vaccines Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 8.60 % during the forecast period (2022-2029).

Vaccines are a biological preparation that aids in fighting against diseases and boosting immunity. It contains an agent related to a disease-causing organism and is made from a killed form of microbes. According to the World Health Organization (WHO), currently, licensed vaccines are available to avoid over twenty-five infections. The vaccine's effectiveness depends on disease pathophysiology, the stain of the vaccine, ethnicity, the schedule of the vaccination, and genetic predisposition. As globalization rises, international traveling will keep increasing, creating the demand for travel vaccines. Moreover, vaccines are broadly used as a preventive measure counter to known infectious diseases. The travelers are educated to adhere to the region-specific immunization plan. The number of diseases and viruses that have afflicted the sector has increased swiftly in the past few decades, and certainly, not enough vaccinations have been developed against them. The increased awareness has obliged people to take the necessary vaccinations without giving them a second thought.

Market Dynamics: Growing tourism and travel industry drives market growth

The growing touring industry and surge in the incidence of travel-related diseases are the major growth driver for the traveler vaccine market. Growing investment in the R&D of new vaccines by pharmaceutical and biotechnology companies and the growing adoption of vaccines by international travelers have prompted the demand for traveler vaccines. Furthermore, the growing government initiatives and rising awareness through electronic & print media are the factors that are expected to enhance the growth of the market. However, lack of expertise in the production of vaccines and weak cold supply chain management are the factors limiting the market's growth.

Also, the low risk of serious side effects helps to grow the market. Extreme low risks of serious side effects on the fetus, along with suitable educational & awareness programs through various nonprofit organizations, are factors that support the market growth. Rising inclinations for outsourcing vaccines in emerging and underdeveloped countries offer the opportunity to boost the traveler's vaccine market. It is expected to grow with the increase in outbound travel and vaccination coverage due to its awareness.

Market Segmentation: The tourist's segment will project the fastest growth in the market throughout the forecast period

Traveller's vaccines are further segmented based on an application that includes tourists, students, workers and others

The tourist segment is anticipated to grow with a high CAGR over the forecast period. World tourism organization stated that Global tourism experienced a mild 4% upturn in 2021, with 15 million more international tourist arrivals (overnight visitors) than in 2020. Europe and the Americas recorded the strongest results by region relative to 2020, with arrivals up 19% and 17%, respectively. Many of these travelers' journeys start in developed countries to regions with endemic diseases. Moreover, regulatory authorities globally have also instructed that travelers should be vaccinated before traveling to disease-prone regions.

Based on the type, the traveller's vaccines market has been classified into Meningococcal Vaccine, Japanese Encephalitis Vaccine, Yellow Fever Vaccine, Hepatitis Vaccine, Cholera Vaccine and Others.

Hepatitis Vaccine held significant share in the market. A key driver for the hepatitis vaccine market is the increasing prevalence of HBV infected populations, particularly in the WHO Western Pacific Region. Governments globally recognize the HBV vaccine as the only cost-effective way to primary infection prevention.

Geographical Penetration: North America is the dominating region during the forecast period.

Based on geography, the study analyzes the traveller's vaccines market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Geographically, North America is likely to dominate the human vaccines market in the global market over the forecast period. The combination vaccines segment is expected to expand at a high share in North America, followed by the recombinant and attenuated vaccines segments. In Europe, an increase in demand for vaccination and an increase in R&D expenditure boost the traveler's vaccines market.

Moreover, Asia Pacific is an emerging market for traveler's vaccines due to the improving healthcare infrastructure and rising government expenditures for organizing educational & awareness programs. In the Middle East and African countries, the advancement of the healthcare industry and economy helps to enhance travelers' vaccine market. However, affordability issues are factors restraining the market growth. The Government of Saudi Arabia operates routine vaccination programs for influenza, flu, and other vaccines in the country, generating an opportunity in the traveler's vaccine market.

Competitive Landscape:

The traveler's vaccines market is highly competitive, owing to the presence of big food brands. The key traveler's vaccines players which are contributing to the growth of the global market include Baxter International, Abbott Laboratories, Crucell Vaccines, Pfizer Inc., Emergent BioSolutions, Hoffman-La Roche Ltd., Dynavax Technologies Corporation, GSK group of companies, Shenzhen Kangtay Biological Products Co. Ltd., Takeda Pharmaceuticals U.S.A. Inc., Zydus Cadila, among others. The major players are adopting new product launches and expansion strategies for global growth in the traveler's vaccines market. Some key players follow acquisition strategies to expand their business. For instance, in December 2021, Baxter, a global MedTech leader, completed the acquisition of Hillrom. This acquisition accelerates the company's vision for transforming healthcare and advancing patients care worldwide. Baxter, a clinical-stage biopharmaceutical company, paid $156.00 in cash for each outstanding share of Hillrom common stock for a purchase price of $10.5 billion. In June 2022, Pfizer completed the acquisition with ReViral. This acquisition helped to expand a portfolio of promising therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to block the fusion of the RSV virus to the host cell. This acquisition further demonstrated advancing pioneering science. In December 2021, Pfizer acquired Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for treating several immuno-inflammatory diseases, for $100 per share in a total equity value of approximately $6.7 billion.

COVID-19 Impact: Negative impact on the global traveler's vaccines market.

COVID-19 has certainly hampered the growth of the traveler's vaccine globally. The ban on international traveling by the governments has declined the number of international visits in 2020. Therefore, the demand for traveler's vaccines declined and led to a downfall in the market value in 2020 and subsequent years.

Post COVID-19, it is expected that the travel and tourism industry get the boom, and the demand for traveler's vaccines also will gain traction due to increasing concern for health safety. Traveler's vaccines have a very rapid growth in the upcoming year due to this pandemic.

The global traveler's vaccines market report would provide an access to approximately 56 market data tables, 47 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing tourism and travel industry
    • 4.1.2. Restraints:
      • 4.1.2.1. Low risk of side effects
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
  • 7.3. Market Attractiveness Index, By Type Segment
    • 7.3.1. Meningococcal Vaccine*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Japanese Encephalitis Vaccine
    • 7.3.3. Yellow Fever Vaccine
    • 7.3.4. Hepatitis Vaccine
    • 7.3.5. Cholera Vaccine
    • 7.3.6. Others

8. By Application

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 8.3. Market Attractiveness Index, By Application Segment
    • 8.3.1. Tourists*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Students
    • 8.3.3. Workers
    • 8.3.4. Others

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Baxter International*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Abbott Laboratories
  • 11.3. Crucell Vaccines
  • 11.4. Pfizer Inc.
  • 11.5. Emergent BioSolutions
  • 11.6. Hoffman-La Roche Ltd.
  • 11.7. Dynavax Technologies Corporation
  • 11.8. GSK group of companies
  • 11.9. Shenzhen Kangtay Biological Products Co. Ltd.
  • 11.10. Takeda Pharmaceuticals U.S.A. Inc
  • 11.11. Zydus Cadila (List Not Exhaustive)

12. Premium Insights

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us